<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">IJO</journal-id><journal-id journal-id-type="publisher-id">Indian J Ophthalmol</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Wolters Kluwer - Medknow</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38389249</article-id><article-id pub-id-type="pmc">PMC467026</article-id>
<article-id pub-id-type="publisher-id">IJO-72-441</article-id><article-id pub-id-type="doi">10.4103/IJO.IJO_1466_23</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Study on the mechanism of 20-hydroxyeicosatetraenoic acid in retinal ischemia&#x02013;reperfusion injury</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lv</surname><given-names>Liang</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Li-Xiao</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Fei-Fei</given-names></name><xref rid="aff1" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Ophthalmology, The Fifth Clinical College of Zhengzhou University, Zhengzhou, China</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Dr. Liang Lv, Department of Ophthalmology, The Fifth Clinical College of Zhengzhou University, No. 3 of Kangfu Front Street, Erqi District, Zhengzhou - 450052, China. E-mail: <email xlink:href="lvliang3107@163.com">lvliang3107@163.com</email></corresp></author-notes><!--Fake ppub date generated by PMC from publisher
					pub-date/@pub-type='epub-ppub'--><pub-date pub-type="ppub"><month>5</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>23</day><month>2</month><year>2024</year></pub-date><volume>72</volume><issue>Suppl 3</issue><fpage>S441</fpage><lpage>S447</lpage><history><date date-type="received"><day>05</day><month>6</month><year>2023</year></date><date date-type="rev-recd"><day>24</day><month>10</month><year>2023</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2024 Indian Journal of Ophthalmology</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title>Purpose:</title><p>To explore the effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on retinal ischemia&#x02013;reperfusion injury (RIRI) and the protective effect of N&#x02010;hydroxy&#x02010;N&#x02019;&#x02010;(4&#x02010;n&#x02010;butyl&#x02010;2&#x02010;methylphenyl)formamidine (HET0016) on RIRI.</p></sec><sec id="st2"><title>Methods:</title><p>Male Sprague&#x02013;Dawley rats were randomly divided into the normal control group, experimental model group (RIRI group), experimental solvent group (RIRI + solvent group), and experimental treatment group (RIRI + HET0016 group).</p></sec><sec id="st3"><title>Results:</title><p>The levels of 20-HETE, tumor necrosis factor-&#x003b1; (TNF-&#x003b1;), and interleukin-1&#x003b2; (IL-1&#x003b2;) in the retina of rats at 24 h after reperfusion were measured by enzyme-linked immunosorbent assay. Hematoxylin&#x02013;eosin staining was used to observe the retinal morphological and thickness changes at 24 h, 48 h, and 7 days after reperfusion. The number and localized expression of matrix metalloproteinase-9&#x02013;positive cells in the retina of the rats at 24 h after reperfusion and the activation and localized expression of retinal microglia at 48 h after reperfusion were measured using an immunohistochemical method. The nuclear metastasis of nuclear factor kappa-B (NF-&#x003ba;B, p65) cells at 24 h after reperfusion was observed using an immunofluorescence method.</p></sec><sec id="st4"><title>Conclusion:</title><p>Overall, 20-HETE might activate microglia to aggravate RIRI by the NF-&#x003ba;B pathway, but HET0016 has significant protective effects for the retina.</p></sec></abstract><kwd-group><kwd>20-hydroxyeicosatetraenoic acid</kwd><kwd>N&#x02010;hydroxy&#x02010;N&#x02019;&#x02010;(4&#x02010;n&#x02010;butyl&#x02010;2&#x02010;methylphenyl)formamidine</kwd><kwd>nuclear factor kappa-B</kwd><kwd>retinal ischemia&#x02013;reperfusion injury</kwd></kwd-group></article-meta></front><body><p>The retina plays a crucial role in the visual pathway by sensing light stimuli and transmitting neural signals.[<xref rid="R1" ref-type="bibr">1</xref>] Ischemic retinal diseases account for a significant proportion of ocular diseases, and common causes include hypoperfusion retinopathy induced by inadequate ocular arterial blood supply, ocular ischemic syndrome, central retinal artery occlusion, central retinal vein occlusion, intraocular hypertension, and ophthalmic procedures affecting retinal blood flow.[<xref rid="R2" ref-type="bibr">2</xref>] Retinal ischemia&#x02013;reperfusion injury (RIRI) represents a crucial pathological mechanism underlying diabetic retinopathy (DR), glaucoma, and retinal vascular occlusive diseases, promoting the apoptosis of retinal ganglion cells (RGCs), attributable to retinal dysfunction and visual impairment.[<xref rid="R3" ref-type="bibr">3</xref><xref rid="R4" ref-type="bibr">4</xref>] RIRI management mainly focuses on neuroprotection and treatments against oxidative stress and free radicals, calcium overload, leukocyte actions and inflammatory responses, glutamate&#x02010;mediated excitotoxicity, and apoptosis.[<xref rid="R5" ref-type="bibr">5</xref>]</p><p>Patients with DR have been found to have an increased level of 20&#x02010;hydroxyeicosatetraenoic acid (20&#x02010;HETE) in the vitreous body.[<xref rid="R6" ref-type="bibr">6</xref>] This is a bioactive arachidonic acid generated through cytochrome P450 catalysis. It is reported to play a key role in regulating the myogenic contraction of arteriolar smooth muscles in the kidney, brain, skeletal muscles, and mesentery.[<xref rid="R7" ref-type="bibr">7</xref>] Evidence shows that 20&#x02010;HETE can activate the nuclear factor kappa-B (NF&#x02010;&#x003ba;B) signaling pathway, promote the release of inflammatory cytokines, stimulate microglial proliferation, upregulate matrix metalloproteinase&#x02010;9 (MMP&#x02010;9) expression, and eventually lead to tissue damage.[<xref rid="R8" ref-type="bibr">8</xref>] The 20&#x02010;HETE inhibitor N&#x02010;hydroxy&#x02010;N&#x02019;&#x02010;(4&#x02010;n&#x02010;butyl&#x02010;2&#x02010;methylphenyl) formamidine (HET0016) has been found to alleviate inflammatory reactions and tissue edema, inhibit microglial activation, and downregulate MMP&#x02010;9 expression through the significant reduction of 20&#x02010;HETE.[<xref rid="R9" ref-type="bibr">9</xref>]</p><p>To date, the secretion level of 20&#x02010;HETE and the related mechanism responsible for retinal injury in RIRI remain a research gap. In the current study, a rat model of RIRI is established via the application of high intraocular pressure (IOP) and intravenous injection of HET0016 solution. This study investigates the pathological mechanism of 20&#x02010;HETE in RIRI and explores the protective effects of HET0016 on RIRI by using enzyme-linked immunosorbent assay (ELISA), immunohistochemistry (IHC), and immunofluorescence (IF) techniques, aiming to provide experimental evidence for the treatment of RIRI.</p><sec sec-type="methods" id="sec1-1"><title>Methods</title><sec id="sec2-1"><title>Laboratory animals</title><p>Male, specific-pathogen-free Sprague&#x02013;Dawley rats weighing 200 &#x000b1; 20 g, with clear refraction, round pupils, normal light response, and no abnormalities upon dilated fundus examination, were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. The breeding conditions and experimental procedures were in line with the Administrative Regulations on Laboratory Animal Management set out by the State Scientific and Technological Commission. This study obtained approval from the Animal Ethics Committee.</p></sec><sec id="sec2-2"><title>Animal model</title><p>An animal model of RIRI was established following the method previously proposed by Hartsock <italic toggle="yes">et al.</italic>[<xref rid="R10" ref-type="bibr">10</xref>] Rats in the RIRI group were anesthetized with 0.3% pentobarbital sodium (1.5 mL/100 g) via intraperitoneal injection. Compound tropicamide was used for pupil dilation, followed by the application of proparacaine hydrochloride eye drops. A 30&#x02010;G needle was inserted into the anterior chamber for standard infusion without causing corneal penetration or damage to the iris or lens. The other end of the needle was connected to physiological saline and elevated to a distance of 150 cm from the rat&#x02019;s eyeball, resulting in an IOP of 109.7 mmHg. High perfusion pressure was applied to the anterior chamber for 60 min before needle removal. As the white retina turned orange&#x02010;red, tetracycline ointment was applied.</p></sec><sec id="sec2-3"><title>Experimental groups</title><p>A total of 112 rats were randomly divided into the normal control (CON) group, model (RIRI) group, solvent treatment (RIRI + solvent) group, and HET0016 treatment (RIRI + HET0016) group, with 28 rats in each group. To build an RIRI model, the RIRI, RIRI + solvent, and RIRI + HET0016 groups were further divided into three subgroups, each according to the following time points of reperfusion: 24 h, 48 h, and 7 days after reperfusion. In the RIRI + HET0016 group, the rats were intravenously injected with HET0016 solution (1 mg/kg) via the tail vein 5&#x02013;10 min before reperfusion. In the RIRI + solvent group, the rats received an equal volume of 15% hydroxypropyl&#x02010;&#x003b2;&#x02010;cyclodextrin solution through the tail vein 5&#x02013;10 min before reperfusion.</p></sec><sec id="sec2-4"><title>Reagents and consumables</title><p>HET0016 (#HY-124527, MedChemExpress, USA), hydroxypropyl&#x02010;&#x003b2;&#x02010;cyclodextrin (#C7070, Solarbio China), NF-&#x003ba;B p65 antibody (#8242, Cell Signaling Technology, USA), IBA1 antibody (#DF6442, Affinity, USA), MMP&#x02010;9 antibody (#TA5228, Abmart Medical Technology, China), rat tumor necrosis factor-&#x003b1; (TNF&#x02010;&#x003b1;) ELISA kit (#ml002859, Enzyme&#x02010;linked Biotechnology, China), and rat 20&#x02010;HETE ELISA kit (#ml038319, Enzyme&#x02010;linked Biotechnology, China).</p></sec><sec id="sec2-5"><title>Preparation of key reagents</title><sec id="sec3-1"><title>Preparation of 15% hydroxypropyl&#x02010;&#x003b2;&#x02010;cyclodextrin solution</title><p>A total of 15 g of hydroxypropyl&#x02010;&#x003b2;&#x02010;cyclodextrin powder was weighed using a precision balance. It was dissolved in 0.9% saline solution until no sediment was visible, and then, more saline was added until the volume reached 100 mL.</p></sec><sec id="sec3-2"><title>Preparation of 1 mg/mL HET0016 solution.[<xref rid="R11" ref-type="bibr">11</xref><xref rid="R12" ref-type="bibr">12</xref><xref rid="R13" ref-type="bibr">13</xref>]</title><p>An adequate amount of HET0016 according to body weight (1 mg/kg) was calculated and dissolved in the aforementioned 15% hydroxypropyl&#x02010;&#x003b2;&#x02010;cyclodextrin solution. The concentration was 1 mg/mL, and the solution was clear and free of sediment.</p></sec><sec id="sec3-3"><title>Preparation of 0.3% phosphate&#x02010;buffered saline with Tween 20</title><p>Next, 300 &#x003bc;L of Tween 20 was added to 100 mL of 0.1-M phosphate&#x02010;buffered saline (PBS) at a pH of 7.4 and mixed thoroughly for future use.</p></sec><sec id="sec3-4"><title>Preparation of 3% bovine serum albumin solution</title><p>A total of 3 g of powdered bovine serum albumin was dissolved in 100 mL of 0.3% PBST solution. The solution was stirred until it became clear and transparent.</p></sec></sec><sec id="sec2-6"><title>Outcome measures and assays</title><sec id="sec3-5"><title>Determination of retinal levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1; and interleukin-1&#x003b2; at 24 h of reperfusion by enzyme-linked immunosorbent assay</title><p>Thirty&#x02010;two rats meeting the inclusion criteria were randomly divided into the CON group, RIRI group, RIRI + solvent group, and RIRI + HET0016 group, with eight rats in each group. The rats were sacrificed 24 h after reperfusion, and their retinal tissues were harvested and prepared into protein extracts. Standard ELISA was performed to plot a standard curve and determine the equation. Dilutions were calculated using the optical density values of the samples and the equation, and the actual concentration was the diluted concentration multiplied by the dilution ratio.</p></sec><sec id="sec3-6"><title>Preparation of paraffin sections</title><p>Eighty rats fulfilling the inclusion criteria were randomly assigned to the CON group (n = 8), RIRI group (n = 24), RIRI + solvent group (n = 24), and RIRI + HET0016 group (n = 24). Furthermore, the RIRI, RIRI + HET0016, and RIRI + solvent groups were divided into 24-h, 48-h, and 7-day reperfusion subgroups (n = 8 in each group). Eyeball specimens were collected to prepare paraffin blocks and sections.</p></sec><sec id="sec3-7"><title>Hematoxylin and eosin staining</title><p>Hematoxylin and eosin (HE) staining was performed to observe the retinal morphology at 24 h, 48 h, and 7 days of reperfusion. Photomicrographs were taken by selecting the retinal area 1 mm away from the optic papilla on both sides by using an optical microscope.</p></sec><sec id="sec3-8"><title>IHC</title><p>Immunohistochemistry was conducted to visualize the expression and localization of MMP&#x02010;9&#x02013;positive cells in the retina at 24 h of reperfusion, followed by the detection of microglial cell count and location at 48 h of reperfusion. Three random fields were selected for photomicrography.</p></sec><sec id="sec3-9"><title>Immunofluorescence staining</title><p>The IF staining was performed to observe the nuclear translocation of p65 in retinal cells at 24 h of reperfusion. Three fields were randomly selected for photomicrography and analysis, with the nucleus blue&#x02010;stained and p65 red&#x02010;stained.</p></sec></sec><sec id="sec2-7"><title>Statistical analysis</title><p>The statistical analysis was performed using SPSS 25.0. All measurement data were presented as mean &#x000b1; standard deviation (x &#x000b1; s), and the differences between groups were evaluated using one&#x02010;way analysis of variance. When the homogeneity of variance was satisfied, multiple comparisons were conducted using the Student&#x02013;Newman&#x02013;Keuls test. In cases of heterogeneity of variance, non&#x02010;parametric tests (Mann&#x02013;Whitney U test) were employed for multiple comparisons. The significance level was set at &#x003b1; =0.05. The software ImageJ was used for counting positive cells and measuring retinal thickness, while another software, GraphPad, was employed to generate statistical graphs.</p></sec></sec><sec sec-type="results" id="sec1-2"><title>Results</title><sec id="sec2-8"><title>Determination of retinal levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and interleukin 1&#x003b2; at 24 h of reperfusion by ELISA</title><p>The RIRI and RIRI + solvent groups had significantly higher levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and interleukin 1&#x003b2; (IL&#x02010;1&#x003b2;) in the retina as compared with the CON group (<xref rid="IJO.IJO_1466_23-F1" ref-type="fig">Fig. 1</xref>, all <italic toggle="yes">P</italic> &#x0003c; 0.05). However, the differences were insignificant between the RIRI and RIRI + solvent groups (<italic toggle="yes">P</italic> = 0.071, 0.962, and 0.624, respectively). In contrast, the RIRI + HET0016 group showed reduced levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and IL&#x02010;1&#x003b2; in comparison with the RIRI and RIRI + solvent groups, and the differences were statistically significant (all <italic toggle="yes">P</italic> &#x0003c; 0.05). Moreover, the levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and IL&#x02010;1&#x003b2; in the RIRI + HET0016 group were higher than those in the CON group, and the differences were statistically significant (all <italic toggle="yes">P</italic> &#x0003c; 0.05). These results indicated that HET1006 can significantly inhibit the increase of inflammatory factor secretion caused by RIRI.</p><fig position="float" id="IJO.IJO_1466_23-F1"><label>Figure 1</label><caption><p>Determination of retinal levels of 20-HETE, TNF-&#x003b1;, and IL-1&#x003b2; by ELISA. Note: A: 20-HETE, B: TNF-&#x003b1;, C: IL-1&#x003b2;; CON group (n = 28): Normal control group, RIRI group (n = 28): Model group, RIRI + solvent group (n = 28): Solvent treatment group, RIRI + HET0016 group (n = 28): HET0016 treatment group; 20-HETE: 20-hydroxyeicosatetraenoic acid. (In Figure 1a, *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group. In Figure 1b, *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group. In Figure 1c, *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group.)</p></caption><graphic xlink:href="IJO-72-441-g001" position="float"/></fig></sec><sec id="sec2-9"><title>HE staining&#x02013;based morphological changes in the retina at 24 h, 48 h, and 7 days of reperfusion</title><p>The retina consists of 10 layers, and three distinct layers can be observed under light microscopy, as follows: the ganglion cell layer (GCL), the inner nuclear layer (INL), and the outer nuclear layer. HE staining revealed that the retinas in the CON group had well-organized layers and clear structural integrity. At 24 h and 48 h post modeling, the retinas in the RIRI and RIRI + solvent groups showed disrupted morphology, loose cell arrangement, vacuoles, nuclear condensation, and signs of swelling and thickening. Compared with the RIRI and RIRI + solvent groups, the RIRI + HET0016 group showed reduced pathological changes in the retinas, with a more orderly cell arrangement and lessened swelling. At 7 days post modeling, the RIRI and RIRI + solvent groups exhibited reduced retinal thickness, nuclear dissolution, and decreased RGCs. In contrast, the RIRI + HET0016 group experienced an increase in retinal thickness as well as in the number of RGCs [<xref rid="IJO.IJO_1466_23-F2" ref-type="fig">Fig. 2</xref>].</p><fig position="float" id="IJO.IJO_1466_23-F2"><label>Figure 2</label><caption><p>HE staining of the retina at 7 days of reperfusion (100&#x000d7;). Note: CON group (n = 28): Normal control group, RIRI group (n = 28): Model group, RIRI + solvent group (n = 28): Solvent treatment group, RIRI + HET0016 group (n = 28): HET0016 treatment group</p></caption><graphic xlink:href="IJO-72-441-g002" position="float"/></fig></sec><sec id="sec2-10"><title>IHC detection of MMP&#x02010;9&#x02013;positive cell expression and localization in the retina at 24 h of reperfusion</title><p>The CON group showed minimal expression of MMP&#x02010;9&#x02013;positive cells, while the RIRI and RIRI + solvent groups exhibited increased expression of MMP&#x02010;9 in all layers of the retina, especially in the GCL [<xref rid="IJO.IJO_1466_23-F3" ref-type="fig">Fig. 3</xref>]. The MMP&#x02010;9&#x02013;positive cell expression of the RIRI and RIRI + solvent groups was significantly different from that of the CON group (<italic toggle="yes">P</italic> &#x0003c; 0.05). However, no significant difference in MMP&#x02010;9&#x02013;positive cell expression was observed between the RIRI and RIRI + solvent groups (<italic toggle="yes">P</italic> = 0.897). Compared with the RIRI and RIRI + solvent groups, the RIRI + HET0016 group showed a significant reduction in MMP&#x02010;9&#x02013;positive cells (<italic toggle="yes">P</italic> &#x0003c; 0.05). Compared with the CON group, the RIRI + HET0016 group had a significantly higher MMP&#x02010;9&#x02013;positive cell count (<italic toggle="yes">P</italic> &#x0003c; 0.05).</p><fig position="float" id="IJO.IJO_1466_23-F3"><label>Figure 3</label><caption><p>IHC detection of MMP-9-positive cell count. (a) Representative images of MMP-9 immunohistochemistry (400&#x000d7;), (b) Quantitative results of MMP-9 immunohistochemistry. Note: CON group (n = 28): Normal control group, RIRI group (n = 28): Model group, RIRI + solvent group (n = 28): Solvent treatment group, RIRI + HET0016 group (n = 28): HET0016 treatment group. IHC staining was conducted to determine MMP-9-positive cell count in the retina, where positive cells appeared dark brown with blue-stained nuclei. *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group</p></caption><graphic xlink:href="IJO-72-441-g003" position="float"/></fig></sec><sec id="sec2-11"><title>IHC detection of microglial activation status and localization at 48 h of reperfusion</title><p>Microglial cell expression was detected using its specific marker IBA1. A small number of activated microglial cells were observed in the CON group, while significantly increased microglial activation was noted in the RIRI and RIRI + solvent groups, characterized by enlarged cell bodies typically distributed in the GCL and inner plexiform layer (<xref rid="IJO.IJO_1466_23-F4" ref-type="fig">Fig. 4</xref>, <italic toggle="yes">P</italic> &#x0003c; 0.05). The RIRI and RIRI + solvent groups showed no significant difference in microglial activation (<italic toggle="yes">P</italic> = 0.713). Compared with the RIRI and RIRI + solvent groups, the RIRI + HET0016 group experienced a significant reduction in activated microglial cells (<italic toggle="yes">P</italic> &#x0003c; 0.05). Compared with the CON group, the RIRI + HET0016 group had a significantly higher number of activated microglial cells (<italic toggle="yes">P</italic> &#x0003c; 0.05).</p><fig position="float" id="IJO.IJO_1466_23-F4"><label>Figure 4</label><caption><p>IHC detection of IBA1-positive cell count. (a) Representative images of IBA1 immunohistochemistry (400&#x000d7;), (b) Quantitative results of IBA1 immunohistochemistry. Note: CON group (n = 28): Normal control group, RIRI group (n = 28): Model group, RIRI + solvent group (n = 28): Solvent treatment group, RIRI + HET0016 group (n = 28): HET0016 treatment group. *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group</p></caption><graphic xlink:href="IJO-72-441-g004" position="float"/></fig></sec><sec id="sec2-12"><title>IF staining of p65 localization at 24 h of reperfusion</title><p>The IF results of p65 are shown in <xref rid="IJO.IJO_1466_23-F5" ref-type="fig">Fig. 5</xref>. In the CON group, p65 was mostly expressed in the cytoplasm but rarely in the nucleus. Compared with the CON group, the RIRI and RIRI + solvent groups showed significantly increased nuclear expression of p65, primarily in the GCL and INL (<italic toggle="yes">P</italic> &#x0003c; 0.05, respectively), but the difference between the RIRI group and the RIRI + solvent group lacked statistical significance (<italic toggle="yes">P</italic> = 0.603). In the RIRI + HET0016 group, the nuclear translocation of p65 was significantly reduced compared with that in the RIRI and RIRI + solvent groups (<italic toggle="yes">P</italic> &#x0003c; 0.05).</p><fig position="float" id="IJO.IJO_1466_23-F5"><label>Figure 5</label><caption><p>IF staining of p65 nuclear translocation (a) Representative images of p65 immunofluorescence (400&#x000d7;), (b) Quantitative results of p65 immunofluorescence. Note: CON group (n = 28): Normal control group, RIRI group (n = 28): Model group, RIRI + solvent group (n = 28): Solvent treatment group, RIRI + HET0016 group (n = 28): HET0016 treatment group. *<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the CON group; #<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI group; &#x02020;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + solvent group; &#x02021;<italic toggle="yes">P</italic> &#x0003c; 0.05 compared with the RIRI + HET0016 group</p></caption><graphic xlink:href="IJO-72-441-g005" position="float"/></fig></sec></sec><sec sec-type="discussion" id="sec1-3"><title>Discussion</title><p>RIRI can induce RGC apoptosis and eventually lead to physiological dysfunction of the retina.[<xref rid="R14" ref-type="bibr">14</xref>] Palmhof <italic toggle="yes">et al.</italic>[<xref rid="R15" ref-type="bibr">15</xref>] reported that damage to RGCs occurs during the early phase of reperfusion. RIRI has been found to play a role in the NF&#x02010;&#x003ba;B signaling pathway,[<xref rid="R16" ref-type="bibr">16</xref>] apoptotic signaling pathway,[<xref rid="R17" ref-type="bibr">17</xref>] and autophagy signaling pathway.[<xref rid="R18" ref-type="bibr">18</xref>] Despite the current knowledge of these complex signaling pathways and related pathological mechanisms, there is a lack of effective protection from reperfusion injury. Studies have shown that the 20&#x02010;HETE level is elevated in mouse brain tissue after cerebral ischemia&#x02013;reperfusion,[<xref rid="R19" ref-type="bibr">19</xref>] in the cerebral cortex of mice with traumatic brain injury, in the plasma of patients with ischemic diseases,[<xref rid="R20" ref-type="bibr">20</xref>] and in the vitreous body of patients with DR.[<xref rid="R21" ref-type="bibr">21</xref>] Like 20&#x02010;HETE, epoxyeicosatrienoic acids can also be generated in the retinal circulation and are reported to be associated with retinal angiogenesis under hypoxic conditions.[<xref rid="R22" ref-type="bibr">22</xref>] Nevertheless, very little is known about the relationship between 20&#x02010;HETE and RIRI.</p><p>In this study, the retinal level of 20&#x02010;HETE at 24 h of reperfusion was significantly elevated in the RIRI group and the RIRI + solvent group compared with the CON group. Notably, early intervention with HET0016 resulted in a reduction in the retinal level of 20&#x02010;HETE in the RIRI model. It is believed that the use of HET0016 could reverse the RIRI&#x02010;induced increase in 20&#x02010;HETE secretion and thereby reduce inflammatory responses and tissue edema. Interleukin 1&#x003b2; is an important mediator of immune response in an inflammatory environment. Evidence has shown that increased IOP could activate retinal inflammatory responses, stimulate the release of IL&#x02010;1&#x003b2; and other pro&#x02010;inflammatory molecules, and lead to RIRI. In this study, the retinal levels of 20&#x02010;HETE and the inflammatory cytokines TNF&#x02010;&#x003b1; and IL&#x02010;1&#x003b2; were significantly reduced in the RIRI + HET0016 group as compared with the other groups. The study by Zhang <italic toggle="yes">et al.</italic>[<xref rid="R2" ref-type="bibr">2</xref>] investigated the effect of curcumin on the retinal expression of IL&#x02010;1&#x003b2; in rats with RIRI and discovered that RIRI can be mitigated through IL&#x02010;1&#x003b2; modulation.</p><p>Nuclear factor kappa-B is a nuclear transcription factor ubiquitously present in various cells and is involved in diverse inflammatory and immune responses.[<xref rid="R23" ref-type="bibr">23</xref><xref rid="R24" ref-type="bibr">24</xref>] The NF&#x02010;&#x003ba;B activator 20&#x02010;HETE can stimulate I&#x003ba;B phosphorylation and nuclear translocation of p65 by activating IKK.[<xref rid="R25" ref-type="bibr">25</xref><xref rid="R26" ref-type="bibr">26</xref>] The activation of NF&#x02010;&#x003ba;B leads to increased synthesis of IL&#x02010;1&#x003b2; and TNF&#x02010;&#x003b1;, and these inflammatory cytokines, in turn, activate NF&#x02010;&#x003ba;B, creating a positive feedback loop that exacerbates reperfusion injury.[<xref rid="R27" ref-type="bibr">27</xref>] Matrix metalloproteinases are a class of endopeptidases that require metal (zinc, calcium) ions as cofactors for activity. Matrix metalloproteinase&#x02010;2, MMP&#x02010;9, and MMP&#x02010;14 have been extensively studied compared with other members of the MMP family.[<xref rid="R8" ref-type="bibr">8</xref>] MMP-9 is normally expressed at low levels. However, it can be expressed abnormally or overexpressed under conditions of ischemia, hypoxia, inflammation, and oxidative stress, which can result in neuronal degeneration and necrosis.[<xref rid="R9" ref-type="bibr">9</xref>] Nuclear factor kappa-B can promote MMP&#x02010;9 expression in various cells.[<xref rid="R28" ref-type="bibr">28</xref>] According to the IF staining analysis, p65 was mainly expressed in the cytoplasm in the CON group. After 24 h of modeling, the RIRI and RIRI + solvent groups showed increased nuclear expression of p65. In the RIRI + HET0016 group, the nuclear expression of p65 decreased following early intervention with HET0016. In other words, HET0016 can inhibit the 20&#x02010;HETE&#x02013;induced nuclear translocation of p65 and suppress the activation of the NF&#x02010;&#x003ba;B pathway. The IHC staining results showed minimal expression of MMP&#x02010;9 in the CON group, increased MMP&#x02010;9 expression in the RIRI and RIRI + solvent groups at 24 h of modeling, and a significant reduction in MMP&#x02010;9&#x02013;positive cells in the RIRI + HET0016 group after early intervention with HET0016 as compared with the RIRI and RIRI + solvent groups. It was inferred that HET0016 could reduce the secretion of MMP&#x02010;9 by inhibiting the synthesis of 20&#x02010;HETE, thereby providing some protection for the blood&#x02013;retinal barrier. Wang <italic toggle="yes">et al.</italic>[<xref rid="R29" ref-type="bibr">29</xref>] also demonstrated the protective effect and mechanism of 20&#x02010;HETE in RIRI&#x02010;induced retinal injury by downregulating MMP&#x02010;9 expression.</p><p>Microglial cells are resident immune cells in the central nervous system and the retina.[<xref rid="R30" ref-type="bibr">30</xref>] In the resting state, microglial cells exhibit a highly branched morphology, secrete neurotrophic factors, and serve as scavengers to maintain normal brain and retinal function.[<xref rid="R30" ref-type="bibr">30</xref><xref rid="R31" ref-type="bibr">31</xref>] In the retina of healthy adults, microglial cells can be found around RGC bodies as well as in the outer and inner plexiform layers, where they are responsible for local environment monitoring, metabolic byproduct elimination, cell debris ingestion, and regulation of intercellular communication.[<xref rid="R31" ref-type="bibr">31</xref><xref rid="R32" ref-type="bibr">32</xref>] Proliferation and morphological changes of microglial cells can be ascribed to focal injury, reperfusion injury, aging, and cellular degeneration.[<xref rid="R33" ref-type="bibr">33</xref><xref rid="R34" ref-type="bibr">34</xref><xref rid="R35" ref-type="bibr">35</xref>] Activated microglial cells produce a high level of pro&#x02010;inflammatory cytokines, such as TNF&#x02010;&#x003b1; and IL&#x02010;1&#x003b2;. Retinal and other neuroinflammatory conditions are characterized by microglial activation and the release of pro&#x02010;inflammatory cytokines. In this study, at 24 h of modeling, both the RIRI group and RIRI + solvent group showed increased secretion of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and IL&#x02010;1&#x003b2;, while the early intervention with HET0016 induced reductions in the levels of 20&#x02010;HETE, TNF&#x02010;&#x003b1;, and IL&#x02010;1&#x003b2;. These findings suggested that 20&#x02010;HETE can stimulate the secretion of inflammatory cytokines TNF&#x02010;&#x003b1; and IL&#x02010;1&#x003b2; by retinal cells in RIRI, leading to aggravated inflammatory responses. At 48 h of reperfusion, the RIRI and RIRI + solvent groups showed significant microglial proliferation, whereas early intervention with HET0016 induced a substantial decrease in microglial cells. These results suggest that HET0016 can inhibit 20&#x02010;HETE&#x02013;induced microglial cell proliferation in RIRI.</p><p>In conclusion, the retinal level of 20&#x02010;HETE was found to be elevated 24 h after the establishment of a rat model of RIRI, and the 20&#x02010;HETE inhibitor HET0016 could alleviate reperfusion injury through inhibition of the NF&#x02010;&#x003ba;B signaling pathway, reduced release of related inflammatory cytokines, downregulation of MMP&#x02010;9 expression, and suppression of microglial activation. These findings can provide a research basis for the treatment of RIRI; offer a new approach for preserving vision in patients with glaucoma, ischemic optic neuropathy, and DR; and supply new clues for further investigations into the underlying mechanisms of RIRI.</p></sec><sec sec-type="conclusion" id="sec1-4"><title>Conclusion</title><p>20-HETE can activate microglia through NF-&#x003ba;B pathway to participate in retinal ischemia-reperfusion injury in rats. HET0016 treatment can reduce the pathological changes of the retina.</p><sec id="sec2-13"><title>Author contributions</title><p>All authors contributed to data analysis, drafting, and revising the article and have agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.</p></sec><sec sec-type="data-availability" id="sec2-14"><title>Data availability statement</title><p>All data generated or analyzed during this study are included in this published article.</p></sec><sec sec-type="funding-statement" id="sec2-15"><title>Financial support and sponsorship</title><p>This study was supported by the Joint Construction Project of Henan Medical Science and Technology Research Project-Mechanism of 20-HETE controlling NF-&#x003ba;B pathway in RIRI.</p><p>Project number: LHGJ20190423</p></sec><sec sec-type="COI-statement" id="sec2-16"><title>Conflicts of interest</title><p>There are no conflicts of interest.</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bi</surname><given-names>JR</given-names></name>
<name><surname>Liu</surname><given-names>FL</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name></person-group><article-title>Protective effect of artesunate on retinal ischemia-reperfusion injury in rats</article-title><source>Chinese J Chin Ophthalmol</source><year>2021</year><volume>31</volume><fpage>321</fpage><lpage>5</lpage></element-citation></ref><ref id="R2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>N</given-names></name>
<name><surname>Yin</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Xiao</surname><given-names>P</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Effect of curcumin on the expression of interleukin-1&#x003b2;in the retina of rats with retinal ischemia-reperfusion injury</article-title><source>Recent Adv Ophthalmol</source><year>2023</year><volume>43</volume><fpage>178</fpage><lpage>84</lpage></element-citation></ref><ref id="R3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duh</surname><given-names>EJ</given-names></name>
<name><surname>Sun</surname><given-names>JK</given-names></name>
<name><surname>Stitt</surname><given-names>AW</given-names></name></person-group><article-title>Diabetic retinopathy: current understanding, mechanisms, and treatment strategies</article-title><source>JCI Insight</source><year>2017</year><volume>2</volume><fpage>e93751</fpage><pub-id pub-id-type="pmid">28724805</pub-id>
</element-citation></ref><ref id="R4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fortmann</surname><given-names>SD</given-names></name>
<name><surname>Grant</surname><given-names>MB</given-names></name></person-group><article-title>Molecular mechanisms of retinal ischemia</article-title><source>Curr Opin Physiol</source><year>2019</year><volume>7</volume><fpage>41</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">34322649</pub-id>
</element-citation></ref><ref id="R5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>LY</given-names></name>
<name><surname>You</surname><given-names>ZP</given-names></name>
<name><surname>Fan</surname><given-names>HM</given-names></name></person-group><article-title>Research progress in prevention and treatment of retinal ischemia-reperfusion injury with traditional Chinese medicine</article-title><source>Pract Clin Med</source><year>2019</year><volume>20</volume><fpage>101</fpage><lpage>4</lpage></element-citation></ref><ref id="R6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>AL</given-names></name>
<name><surname>Roman</surname><given-names>RJ</given-names></name>
<name><surname>Regan</surname><given-names>KA</given-names></name>
<name><surname>Bolch</surname><given-names>CA</given-names></name>
<name><surname>Chen</surname><given-names>CJ</given-names></name>
<name><surname>Iyer</surname><given-names>SSR</given-names></name></person-group><article-title>Eicosanoid profiles in the vitreous humor of patients with proliferative diabetic retinopathy</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>7451</fpage><pub-id pub-id-type="pmid">33050335</pub-id>
</element-citation></ref><ref id="R7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jia</surname><given-names>CY</given-names></name>
<name><surname>He</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>YS</given-names></name>
<name><surname>Han</surname><given-names>Y</given-names></name></person-group><article-title>The role and mechanism of 20&#x02010;HETE in the development of hypertension</article-title><source>Shandong Med J</source><year>2018</year><volume>58</volume><fpage>85</fpage><lpage>88</lpage></element-citation></ref><ref id="R8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toth</surname><given-names>P</given-names></name>
<name><surname>Csiszar</surname><given-names>A</given-names></name>
<name><surname>Sosnowska</surname><given-names>D</given-names></name>
<name><surname>Tucsek</surname><given-names>Z</given-names></name>
<name><surname>Cseplo</surname><given-names>P</given-names></name>
<name><surname>Springo</surname><given-names>Z</given-names></name>
<etal/></person-group><article-title>Treatment with the cytochrome P450 &#x003c9;-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats</article-title><source>Br J Pharmacol</source><year>2013</year><volume>168</volume><fpage>1878</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23194285</pub-id>
</element-citation></ref><ref id="R9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garcia</surname><given-names>V</given-names></name>
<name><surname>Shkolnik</surname><given-names>B</given-names></name>
<name><surname>Milhau</surname><given-names>L</given-names></name>
<name><surname>Falck</surname><given-names>JR</given-names></name>
<name><surname>Schwartzman</surname><given-names>ML</given-names></name></person-group><article-title>20-HETE activates the transcription of angiotensin-converting enzyme via nuclear factor-&#x003ba;B translocation and promoter binding</article-title><source>J Pharmacol Exp Ther</source><year>2016</year><volume>356</volume><fpage>525</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26699146</pub-id>
</element-citation></ref><ref id="R10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hartsock</surname><given-names>MJ</given-names></name>
<name><surname>Cho</surname><given-names>H</given-names></name>
<name><surname>Wu</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>WJ</given-names></name>
<name><surname>Gong</surname><given-names>J</given-names></name>
<name><surname>Duh</surname><given-names>EJ</given-names></name></person-group><article-title>A mouse model of retinal ischemia-reperfusion injury through elevation of intraocular pressure</article-title><source>J Vis Exp</source><year>2016</year><fpage>54065</fpage><comment>doi: 10.3791/54065</comment><pub-id pub-id-type="pmid">27501124</pub-id>
</element-citation></ref><ref id="R11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>LY</given-names></name>
<name><surname>Wang</surname><given-names>ML</given-names></name>
<name><surname>Wei</surname><given-names>XE</given-names></name>
<name><surname>Li</surname><given-names>WB</given-names></name></person-group><article-title>20-HETE inhibition by HET0016 decreases the blood-brain barrier permeability and brain edema after traumatic brain injury</article-title><source>Front Aging Neurosci</source><year>2018</year><volume>10</volume><fpage>207</fpage><pub-id pub-id-type="pmid">30061822</pub-id>
</element-citation></ref><ref id="R12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mu</surname><given-names>Y</given-names></name>
<name><surname>Klamerus</surname><given-names>MM</given-names></name>
<name><surname>Miller</surname><given-names>TM</given-names></name>
<name><surname>Rohan</surname><given-names>LC</given-names></name>
<name><surname>Graham</surname><given-names>SH</given-names></name>
<name><surname>Poloyac</surname><given-names>SM</given-names></name></person-group><article-title>Intravenous formulation of N-hydroxy-N&#x02019;-(4-n-butyl-2-methylphenyl) formamidine (HET0016) for inhibition of rat brain 20-hydroxyeicosatetraenoic acid formation</article-title><source>Drug Metab Dispos</source><year>2008</year><volume>36</volume><fpage>2324</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">18725506</pub-id>
</element-citation></ref><ref id="R13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>R</given-names></name>
<name><surname>Tian</surname><given-names>Z</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Shu</surname><given-names>S</given-names></name></person-group><article-title>Reactive oxygen species-responsive HET0016 prodrug-loaded liposomes attenuate neuroinflammation and improve neurological deficit in a rat model of juvenile traumatic brain injury</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1153349</fpage><pub-id pub-id-type="pmid">37034179</pub-id>
</element-citation></ref><ref id="R14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mead</surname><given-names>B</given-names></name>
<name><surname>Tomarev</surname><given-names>S</given-names></name></person-group><article-title>Evaluating retinal ganglion cell loss and dysfunction</article-title><source>Exp Eye Res</source><year>2016</year><volume>151</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">27523467</pub-id>
</element-citation></ref><ref id="R15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palmhof</surname><given-names>M</given-names></name>
<name><surname>Frank</surname><given-names>V</given-names></name>
<name><surname>Rappard</surname><given-names>P</given-names></name>
<name><surname>Kortenhorn</surname><given-names>E</given-names></name>
<name><surname>Demuth</surname><given-names>J</given-names></name>
<name><surname>Biert</surname><given-names>N</given-names></name>
<etal/></person-group><article-title>From ganglion cell to photoreceptor layer: Timeline of deterioration in a rat ischemia/reperfusion model</article-title><source>Front Cell Neurosci</source><year>2019</year><volume>13</volume><fpage>174</fpage><pub-id pub-id-type="pmid">31133806</pub-id>
</element-citation></ref><ref id="R16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>N</given-names></name>
<name><surname>Zhang</surname><given-names>M</given-names></name>
<name><surname>Yin</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>N-acetylserotonin alleviated the expression of interleukin-1&#x003b2; in retinal ischemia-reperfusion rats via the TLR4/NF-&#x003ba;B/NLRP3 pathway</article-title><source>Exp Eye Res</source><year>2021</year><volume>208</volume><fpage>108595</fpage><pub-id pub-id-type="pmid">34000276</pub-id>
</element-citation></ref><ref id="R17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qin</surname><given-names>JJ</given-names></name>
<name><surname>Mao</surname><given-names>W</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Sun</surname><given-names>P</given-names></name>
<name><surname>Cheng</surname><given-names>D</given-names></name>
<name><surname>Tian</surname><given-names>S</given-names></name>
<etal/></person-group><article-title>Caspase recruitment domain 6 protects against hepatic ischemia/reperfusion injury by suppressing ASK1</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><fpage>1110</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">29958938</pub-id>
</element-citation></ref><ref id="R18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>G</given-names></name>
<name><surname>Feng</surname><given-names>D</given-names></name>
<name><surname>Zu</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Shi</surname><given-names>X</given-names></name>
<etal/></person-group><article-title>Targeting the miR-665-3p-ATG4B-autophagy axis relieves inflammation and apoptosis in intestinal ischemia/reperfusion</article-title><source>Cell Death Dis</source><year>2018</year><volume>9</volume><fpage>483</fpage><pub-id pub-id-type="pmid">29706629</pub-id>
</element-citation></ref><ref id="R19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Zhu</surname><given-names>H</given-names></name>
<name><surname>Kindy</surname><given-names>MS</given-names></name>
<name><surname>Taheri</surname><given-names>S</given-names></name></person-group><article-title>Cytochrome P450 CYP2E1 suppression ameliorates cerebral ischemia reperfusion injury</article-title><source>Antioxidants (Basel)</source><year>2021</year><volume>10</volume><fpage>52</fpage><pub-id pub-id-type="pmid">33466250</pub-id>
</element-citation></ref><ref id="R20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>W</given-names></name>
<name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Guo</surname><given-names>W</given-names></name>
<name><surname>Luo</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<etal/></person-group><article-title>20-HETE synthesis inhibition attenuates traumatic brain injury-induced mitochondrial dysfunction and neuronal apoptosis via the SIRT1/PGC-1&#x003b1; pathway: A translational study</article-title><source>Cell Prolif</source><year>2021</year><volume>54</volume><fpage>e12964</fpage><pub-id pub-id-type="pmid">33314534</pub-id>
</element-citation></ref><ref id="R21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Waldman</surname><given-names>M</given-names></name>
<name><surname>Peterson</surname><given-names>SJ</given-names></name>
<name><surname>Arad</surname><given-names>M</given-names></name>
<name><surname>Hochhauser</surname><given-names>E</given-names></name></person-group><article-title>The role of 20-HETE in cardiovascular diseases and its risk factors</article-title><source>Prostaglandins Other Lipid Mediat</source><year>2016</year><volume>125</volume><fpage>108</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">27287720</pub-id>
</element-citation></ref><ref id="R22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>MH</given-names></name>
<name><surname>Hsiao</surname><given-names>G</given-names></name>
<name><surname>Al-Shabrawey</surname><given-names>M</given-names></name></person-group><article-title>Eicosanoids and oxidative stress in diabetic retinopathy</article-title><source>Antioxidants (Basel)</source><year>2020</year><volume>9</volume><fpage>520</fpage><pub-id pub-id-type="pmid">32545552</pub-id>
</element-citation></ref><ref id="R23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayden</surname><given-names>MS</given-names></name>
<name><surname>Ghosh</surname><given-names>S</given-names></name></person-group><article-title>NF-&#x003ba;B, the first quarter-century: Remarkable progress and outstanding questions</article-title><source>Genes Dev</source><year>2012</year><volume>26</volume><fpage>203</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">22302935</pub-id>
</element-citation></ref><ref id="R24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tegtmeyer</surname><given-names>N</given-names></name>
<name><surname>Soltan Esmaeili</surname><given-names>D</given-names></name>
<name><surname>Sharafutdinov</surname><given-names>I</given-names></name>
<name><surname>Knorr</surname><given-names>J</given-names></name>
<name><surname>Naumann</surname><given-names>M</given-names></name>
<name><surname>Alter</surname><given-names>T</given-names></name>
<etal/></person-group><article-title>Importance of cortactin for efficient epithelial NF-&#x00138;B activation by Helicobacter pylori, Salmonella enterica and Pseudomonas aeruginosa, but not Campylobacter spp</article-title><source>Eur J Microbiol Immunol (Bp)</source><year>2022</year><volume>11</volume><fpage>95</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">35060920</pub-id>
</element-citation></ref><ref id="R25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>CC</given-names></name>
<name><surname>Gupta</surname><given-names>T</given-names></name>
<name><surname>Garcia</surname><given-names>V</given-names></name>
<name><surname>Ding</surname><given-names>Y</given-names></name>
<name><surname>Schwartzman</surname><given-names>ML</given-names></name></person-group><article-title>20-HETE and blood pressure regulation: clinical implications</article-title><source>Cardiol Rev</source><year>2014</year><volume>22</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">23584425</pub-id>
</element-citation></ref><ref id="R26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>L</given-names></name>
<name><surname>Sch&#x000fc;ler</surname><given-names>R</given-names></name>
<name><surname>Xu</surname><given-names>C</given-names></name>
<name><surname>Seebeck</surname><given-names>N</given-names></name>
<name><surname>Markova</surname><given-names>M</given-names></name>
<name><surname>Murahovschi</surname><given-names>V</given-names></name>
<etal/></person-group><article-title>Arachidonic acid inhibits the production of angiotensin-converting enzyme in human primary adipocytes via a NF-&#x003ba;B-dependent pathway</article-title><source>Ann Transl Med</source><year>2020</year><volume>8</volume><fpage>1652</fpage><pub-id pub-id-type="pmid">33490164</pub-id>
</element-citation></ref><ref id="R27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>IM</given-names></name>
<name><surname>Yang</surname><given-names>CM</given-names></name>
<name><surname>Yang</surname><given-names>CH</given-names></name></person-group><article-title>Chitosan oligosaccharides prevented retinal ischemia and reperfusion injury via reduced oxidative stress and inflammation in rats</article-title><source>Exp Eye Res</source><year>2015</year><volume>130</volume><fpage>38</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">25479043</pub-id>
</element-citation></ref><ref id="R28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Umezawa</surname><given-names>K</given-names></name>
<name><surname>Lin</surname><given-names>Y</given-names></name></person-group><article-title>Inhibition of matrix metalloproteinase expression and cellular invasion by NF-&#x003ba;B inhibitors of microbial origin</article-title><source>Biochim Biophys Acta Proteins Proteom</source><year>2020</year><volume>1868</volume><fpage>140412</fpage><pub-id pub-id-type="pmid">32179183</pub-id>
</element-citation></ref><ref id="R29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Effects of Rapamycin on Matrix Metalloproteinase&#x02010;9 Expression in Retinal Ischemia&#x02010;Reperfusion Injury[D]</article-title><source>Guangxi Medical University,</source><year>2015</year></element-citation></ref><ref id="R30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arcuri</surname><given-names>C</given-names></name>
<name><surname>Mecca</surname><given-names>C</given-names></name>
<name><surname>Bianchi</surname><given-names>R</given-names></name>
<name><surname>Giambanco</surname><given-names>I</given-names></name>
<name><surname>Donato</surname><given-names>R</given-names></name></person-group><article-title>The pathophysiological role of microglia in dynamic surveillance, phagocytosis and structural remodeling of the developing CNS</article-title><source>Front Mol Neurosci</source><year>2017</year><volume>10</volume><fpage>191</fpage><pub-id pub-id-type="pmid">28674485</pub-id>
</element-citation></ref><ref id="R31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salter</surname><given-names>MW</given-names></name>
<name><surname>Stevens</surname><given-names>B</given-names></name></person-group><article-title>Microglia emerge as central players in brain disease</article-title><source>Nat Med</source><year>2017</year><volume>23</volume><fpage>1018</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">28886007</pub-id>
</element-citation></ref><ref id="R32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Redmon</surname><given-names>SN</given-names></name>
<name><surname>Yarishkin</surname><given-names>O</given-names></name>
<name><surname>Lakk</surname><given-names>M</given-names></name>
<name><surname>Jo</surname><given-names>A</given-names></name>
<name><surname>Mustafi&#x00107;</surname><given-names>E</given-names></name>
<name><surname>Tvrdik</surname><given-names>P</given-names></name>
<etal/></person-group><article-title>TRPV4 channels mediate the mechanoresponse in retinal microglia</article-title><source>Glia</source><year>2021</year><volume>69</volume><fpage>1563</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">33624376</pub-id>
</element-citation></ref><ref id="R33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Koren</surname><given-names>EG</given-names></name>
<name><surname>Yu</surname><given-names>C</given-names></name>
<name><surname>Klingeborn</surname><given-names>M</given-names></name>
<name><surname>Wong</surname><given-names>AYW</given-names></name>
<name><surname>Prigge</surname><given-names>CL</given-names></name>
<name><surname>Mathew</surname><given-names>R</given-names></name>
<etal/></person-group><article-title>Microglial function is distinct in different anatomical locations during retinal homeostasis and degeneration</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>723</fpage><lpage>37.e7</lpage><pub-id pub-id-type="pmid">30850344</pub-id>
</element-citation></ref><ref id="R34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>C</given-names></name>
<name><surname>Roubeix</surname><given-names>C</given-names></name>
<name><surname>Sennlaub</surname><given-names>F</given-names></name>
<name><surname>Saban</surname><given-names>DR</given-names></name></person-group><article-title>Microglia versus monocytes: Distinct roles in degenerative diseases of the retina</article-title><source>Trends Neurosci</source><year>2020</year><volume>43</volume><fpage>433</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">32459994</pub-id>
</element-citation></ref><ref id="R35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren</surname><given-names>LM</given-names></name>
<name><surname>Zhang</surname><given-names>YH</given-names></name></person-group><article-title>Houttuynia cordata Thunb rescues retinal ganglion cells through inhibiting microglia activation in a rat model of retinal ischemia-reperfusion</article-title><source>Int J Ophthalmol</source><year>2020</year><volume>13</volume><fpage>1880</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">33344185</pub-id>
</element-citation></ref></ref-list></back></article>